Search results for "protein"

Treatment With Pasteurized C1 Inhibitor Concentrate In Skin Swelling Attacks Of Patients With Hereditary Angioedema

2007

C-reactive protein and family history of myocardial infarction

1999

Effect of ovarian stimulation with recombinant LH/ FSH, recombinant FSH and human menopausal gonadotrophin (hMG) in reducing apoptosis rate in cumulu…

2013

Der Effekt von Neostigmin an der motorischen Endplatte beim Intermediärsyndrom der Alkylphosphatvergiftung

1991

A patient with severe organophosphate intoxication received Neostigmine 1 mg IV during the intermediate syndrome. This dose resulted clinically and neurophysiologically in a marked deterioration of neuro-muscular transmission. This effect of neostigmine on the neuromuscular block during the intermediate syndrome (deterioration) differs from its effect on a similar pattern (improvement), which is seen in the delayed neuropathy following organophosphate exposure. The administration of therapeutic doses of cholinesterase inhibitors in patients with a reduced safety margin due to inhibition of endplate acetylcholinesterase may be dangerous.

Temporal Profile of Gene Induction After Venous Ischemia and Effects of Spreading Depression

2004

Occlusion of two adjacent cortical veins is followed by a widespread reduction of rCBF and the occurrence of small infarcts, which become larger if spreading depression (SD) occurs. The infarct matures over time with TUNEL-positive cells seen in the penumbra up to 4 days after vein occlusion. Caspase inhibition with zVAD.fmk reduces infarct size. Here, the time course of gene expression in the penumbra is compared to that induced by SD alone.

C1 Inhibitor for Routine Prophylaxis in Patients with Hereditary Angioedema: Interim Results from a European Registry Study

2016

SIRT1 regulation of insulin-signalling pathways in liver, white adipose tissue and pancreas during fasting or calorie restriction

2007

In an excellent review by Yang et al.[1], published in issue 5 of Trends in Endocrinology and Metabolism, the involvement of the human sirtuin SIRT1 in nutrient-sensing and insulin-signalling pathways is explained. The regulation of SIRT1 with fasting in liver, pancreas and white adipose tissue is illustrated (see Figure 2 of Yang et al.). We consider that the depiction in the article by Yang et al. could be misleading for the reader, and we propose a modified version (Figure 1).

Patterns of changes of anti‐ADAMTS13 after plasma exchange

2006

An enzyme-linked immunosorbent assay (ELISA) has recently been developed to detect antibodies against the von Willebrand factor-cleaving protease ADAMTS13 in patients with thrombotic thrombocytopenic purpura (TTP). The ELISA is based on incubation of plasma with immobilized recombinant ADAMTS13 followed by visualization of IgG and IgM antibodies by means of secondary enzyme-labeled antibodies [1]. In a recent study, anti-ADAMTS13 IgG antibodies were detected in most patients with TTP (97%) characterized by severe ADAMTS13 deficiency (< 10% of normal) [1]. The ELISA was more sensitive than the standard inhibitor assay based upon ADAMTS13 neutralizing activity, which gave positive results in …

OP0309 Intestinal sclerostin/serotonin axis is modulated by dysbiosis and regulates ilc3 expansion in as patients

2017

Background Sclerostin is an osteocyte-specific factor that binds to low-density lipoprotein receptor-related protein 5 (LRP5) inhibiting the Wnt signaling pathway and possibly contributing to the pathogenesis of Ankylosing spondylitis (AS). Subclinical gut inflammation observed in AS patients is characterized by the presence of dysbiosis and innate immune alterations. In the gut, LRP5 activation by unknown ligands inhibits serotonin production. Serotonin, by inducing glial derived neurotrophic factor (GDNF), controls ILC3 expansion, in the context of glial–ILC3–epithelial cell unit (GIECU). Sclerostin/serotonin axis has been never studied in AS. Objectives Aim of this study was to evaluate …

SPECT-Untersuchungen mit dem 123I-markierten Dopamintransporter-Liganden FP-CIT (DaTSCANTM)

2019

ZusammenfassungDie S1-Leitlinie soll bei der Indikationsstellung, Durchführung, Interpretation und Befundung von SPECT-Untersuchungen des Dopamintransporters (DAT) mit DaTSCANTM unterstützen. Gegenüber der Vorgängerversion von 2007 berücksichtigt die vorliegende Aktualisierung und Überarbeitung die neuere wissenschaftliche Literatur, zwischenzeitlich veröffentlichte Guidelines der europäischen (EANM) und amerikanischen Fachgesellschaften (SNM), sowie die aktuelle Fassung der S3-Leitlinie „Idiopathisches Parkinson-Syndrom“ der Deutschen Gesellschaft für Neurologie. Zudem finden neue technische Möglichkeiten Berücksichtigung.